AssetMark’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$434K Buy
3,883
+3,875
+48,438% +$444K ﹤0.01% 1280
2026
Q2
$917 Hold
8
– – ﹤0.01% 3164
2026
Q1
$666 Buy
8
+2
+33% +$158 ﹤0.01% 3124
2025
Q4
$467 Hold
6
– – ﹤0.01% 3114
2025
Q3
$340 Hold
6
– – ﹤0.01% 2983
2025
Q2
$262 Buy
+6
New +$207 ﹤0.01% 2842

Other funds holding KYMR

AssetMark's KYMR Position: Q3 2026 in Review

AssetMark increased its Kymera Therapeutics (KYMR) stake by 48,438% in Q3 2026, buying an estimated $444K and bringing the position to 3,883 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.

AssetMark first reported a position in KYMR in Q2 2025 and has held it in 6 quarters since. 220 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • AssetMark held 3,883 shares of Kymera Therapeutics worth $434K as of Q3 2026.
  • AssetMark bought 3,875 Kymera Therapeutics shares in Q3 2026, an estimated $444K.
  • Kymera Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1280 holding.
  • AssetMark first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 220 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.